Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 5/20 | 0.56 |
| ▸ | PLG | P00747 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16604401 | 0.92 | F11 (0.56) | F11PLGKMT2AATMMEN1 | |
| SCHEMBL16604359 | 0.92 | PLG (0.58) | F11PLGKMT2AATMMEN1 | |
| SCHEMBL16604355 | 0.91 | F11 (0.56) | F11PLGKMT2AATMMEN1 | |
| SCHEMBL16604396 | 0.91 | F11 (0.61) | F11PLGKMT2AATMMEN1 | |
| SCHEMBL18090722 | 0.89 | PLG (0.58) | F11PLGKMT2AATMMEN1 | |
| SCHEMBL16607730 | 0.89 | F11 (0.57) | F11PLGKMT2AATMMEN1 | |
| SCHEMBL16607712 | 0.89 | PLG (0.58) | F11PLGKMT2AATMMEN1 | |
| SCHEMBL18062667 | 0.89 | F11 (0.57) | F11PLGKMT2AATMMEN1 | |
| SCHEMBL16604517 | 0.88 | F11 (0.72) | F11PLGKLKB1PLAUPRSS1 | |
| SCHEMBL16609331 | 0.88 | PLG (0.57) | F11PLGKMT2AATMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280699-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-29 | — | — | US | disclosed |
| WO-2015044172-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280699-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | PAH, PEPD, AADAT | F11 326/4885PLG 75/4885KMT2A 1451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.